A structural abnormality resulting from the rearrangement of pieces generally between two non-homologous chromosomes. 
Our understanding of carcinogenesis in general, and of leukaemogenesis and lymphomagenesis in particular, has been substantially aided by the discovery of chromosome translocations that transform cells. Identifying the genes at translocation breakpoints was the first step 1, 2 to understanding why chromosome translocations can be oncogenic. Indeed, the first genes identified were oncogenes, MYC and ABL1. Importantly, for those who questioned the role of chromosome translocations in malignancy, these findings resolved any doubts because one of the partner genes in the 8;14 translocation (Burkitt's lymphoma) 3, 4 and the 9;22 translocation (chronic myeloid leukaemia (CML)) 5 was a bona fide oncogene 6,7 . Moreover, for those who had doubts about the relevance of oncogenes to human cancer (they were, after all, generally cloned from experimental mouse tumours), these discoveries showed their relevance to human disease.
However, as translocation breakpoints in acute leukaemia (TABLE 1) , especially acute myeloid leukaemia (AML), were cloned the oncogenic function of the translocated genes became less obvious. For example, the 8;21 translocation (generally found in acute myeloblastic leukaemia) 8 and the 15;17 translocation 9 (found in a rare subtype of AML, acute promyelocytic leukaemia (APL)), each involved a gene crucial for myeloid cell self-renewal, proliferation and/or differentiation, but the partner gene was generally not active in myeloid cells. For the t(8;21) translocation the active gene was AML1 (also known as RUNX1), the DNA binding portion of the α-subunit of core binding factor (CBF) and the inactive gene was ETO (also known as RUNX1T1), a homologue of Drosophila melonogaster nervy that is active in neurons 10 . For the t(15;17) translocation, the active gene was retinoic acid receptor-α (RARA) 11, 12 , the protein product of which is centrally involved in cell differentiation; its partner was a newly identified gene called PML for promyelocytic leukaemia 12 . The fusion proteins AML1-ETO and PML-RARA were found to repress the transcription of wild-type AML1 and RARA target genes, respectively, by recruiting co-repressor complexes containing histone deacetylases (HDACs) (FIG. 1) 13-17 . This was a revelation and immediately pointed to a potential therapeutic strategy, namely transcriptional derepression using pharmacological inhibitors of these co-repressor complex components.
In reality, the prototype for the successful therapeutic targeting of transcriptional repression by fusion proteins present in leukaemia cells has been the use of all-trans retinoic acid (ATRA) for leukaemias with the PML-RARA fusion 18, 19 , whereas HDAC inhibitors have been less successful in treating other acute leukaemias. We now know that histone alterations are not so simple. In fact, the histone code is remarkably complex, with a pattern that includes acetylation and methylation (monomethylation, dimethylation and trimethylation) that seems to proceed in an ordered, complex and incompletely understood fashion 20 . In addition, there is a complex interplay of histone modifications and methylation that determines the state of chromatin structure and is crucial to the regulation of gene transcription 21 . Clearly, to develop effective treatment that reverses transcriptional deregulation in leukaemia, we must understand more about the precise details of these epigenetic marks that are part of the epigenetic code.
Histone deacetylase
An enzyme that regulates chromatin structure and function through the removal of the acetyl group from the lysine residues of core nucleosomal histones.
Histones
The chief protein components of chromatin, which have an important role in DNA packaging, chromosome stabilization and gene expression. Histones form the core component of nucleosomes.
Histone code
The 'rules' governing the pattern of covalent histone tail modifications. Histone tail modifications have an important role in the chromatin structure, and thereby in the regulation of gene expression.
To complicate matters, microRNAs (miRNAs) have been discovered 22 . These small (~22 nucleotides in length) non-protein coding RNAs pair to target mRNAs, usually at the 3′ untranslated regions, leading to the degradation of mRNA or interference with its translation [22] [23] [24] . miRNAs seem to have powerful regulatory effects on many genes in various cancers [24] [25] [26] [27] , including leukaemia [28] [29] [30] [31] . Although our understanding of the regulation of miRNA expression is in its infancy, it is clear that mechanisms such as deletion, amplification and methylation (or other forms of epigenetic repression) are likely to play a part.
Besides the transcriptional and epigenetic deregulation conferred by oncogenic fusion proteins resulting from chromosomal translocations in acute leukaemia, mutations involving specific genes that mediate crucial signalling pathways and mutations in key transcription factors also have a crucial role in leukaemogenesis. For example FMs-related tyrosine kinase 3 (FLT3), KIT, NRAS, KRAS, C/EBP-α (CEBPA) and nucleophosmin (NPM1) mutations have been described in AML, and PAX5, transcription factor 3 (TCF3; also known as E2A), EBF1, LEF1 and IKZF1 (also known as IKAROS) mutations in acute lymphoblastic lukaemia (ALL). The role of these gene mutations in leukaemogenesis is outside the scope of this Review, and has been addressed recently in several other reports [32] [33] [34] . This Review describes the current understanding of epigenetic changes (including miRNA regulation) in acute leukaemias, with a particular focus on acute leukaemias characterized by balanced chromosomal aberrations.
Epigenetic changes in leukaemogenesis
The term epigenetics is generally used to refer to mitotically and meiotically heritable changes in gene expression that occur without alteration of the DNA coding sequence 35 . Epigenetic changes that underlie the development of leukaemia can be in one of two major categories: changes in the DNA methylation state (BOX 1) and alterations in the histone modification pattern
. Recent insights suggest that these two major pathways of epigenetic modification function in concert to regulate gene transcription 21 . In comparison to normal cells, cancer cells exhibit global DNA hypomethylation accompanied by aberrant methylation of cytosine residues that precede guanosine (CpG) islands in gene promoters or coding regions 36 . In the context of leukaemogenesis, aberrant CpG island methylation in promoter regions in genes such as cyclin-dependent kinase inhibitor 2B (CDKN2B), which encodes the tumour suppressor INK4B, and CDKN2A, which encodes the tumour suppressors INK4A and ARF, is a well-described phenomenon. It is associated with transcriptional silencing, which also involves the recruitment of methyl-binding proteins and HDACs to regions near the transcriptional initiation sites 37, 38 . In addition, the recurring chromosomal translocations in AML result in the generation of chimeric fusion genes, which in many cases have been identified as transcriptional regulators (TABLE 1) . several of these fusion proteins result in the development of leukaemia, partly by causing transcriptional deregulation through mechanisms linked to chromatin alterations (FIG. 1) .
Core binding factor leukaemias. The fusion proteins resulting from the chromosomal translocations t(8;21)(q22;q22) (AML1-ETO) and inv(16)(p13q22) (CBFB-MyH11) (TABLE 1) have been identified as transcriptional repressors 15, 39, 40 . These fusion proteins are characterized by the disruption of CBF, a heterodimeric transcription factor that is important in haematopoietic differentiation. CBF consists of an α-unit, AML1 (the DNA binding component), and a β-unit, CBFB, which stabilizes AML1. In mouse models, homozygous loss of Aml1 or Cbfb is characterized by a lack of definitive haematopoiesis and embryonic lethality 41, 42 . Wild-type AML1 functions as a transcriptional activator. By contrast, the fusion proteins repress the transcription of AML1 target genes by either recruiting HDACs directly or cooperating with co-repressors, including nuclear receptor co-repressor 1 (NCOR1), NCOR2 and sIN3A [15] [16] [17] 43 . Recently, AML1-ETO has also been shown to recruit DNA methyltransferase 1 (DNMT1) 44 ; this finding implies that transcriptional silencing of AML1 target genes occurs at least partly through an interplay between histone deacetylation and promoter DNA methy lation. AML1-ETO also at a glance
• Acute leukaemias, arising from neoplastic transformation of uncommitted or partially committed haematopoietic stem cells, are characterized by recurring chromosomal aberrations and gene mutations that are crucial to disease pathogenesis.
• The recurring chromosomal translocations in acute myeloid leukaemia (AML) result in the generation of chimeric fusion proteins that in many cases function as transcriptional regulators. These include AML1-ETO (generated by a translocation between chromosomes 8 and 21, t(8;21)); CBFB-MYH11 (generated by an inversion of chromosome 16, inv(16) or t(16;16)); PML-RARA (generated by t(15;17)); MOZ-CBP (generated by t(8;16)); MORF-CBP (generated by t(10;16)); MOZ-TIF2 (generated by inv(8)); and MLL fused with various partners (generated by t(11q23)). They contribute to leukaemogenesis, at least in part by causing transcriptional deregulation through epigenetic modifications.
• Epigenetic modifications, including DNA methylation, DNA demethylation and histone changes, lead to the activation or repression of gene expression. Aberrant epigenetic changes occur frequently in acute leukaemias. Fusion genes resulting from chromosome translocations can be regulators or mediators of the epigenetic machinery.
• MicroRNA (miRNA) regulation may also considerably contribute to leukaemogenesis. Some miRNAs function as oncogenes or tumour suppressor genes in acute leukaemias. miRNA signatures correlate with cytogenetic and molecular subtypes of acute leukaemias, and some miRNA signatures are associated with outcome or survival of acute leukaemias.
• Not only do miRNAs function in an epigenetic manner by post-transcriptional regulation of target genes, but they can also be targets of the epigenetic machinery and effectors of DNA methylation and histone modifications. These functions might be involved in leukaemogenesis.
• Although the genetic heterogeneity of acute leukaemias poses therapeutic challenges, drugs or small molecules that target components of the epigenetic machinery hold great promise in the treatment of leukaemias. The use of all-trans retinoic acid in the therapy of acute promyelocytic leukaemia is one of the best known and most successful examples of targeted therapy involved in epigenetic changes; progress has also been made in the clinical trials of histone deacetylase inhibitors and DNA methyltransferase inhibitors. However, more effective treatment strategies are needed.
Normal haematopoiesis
A developmental process by which all types of blood cells are continuously produced by rare pluripotent self-renewing haematopoietic stem cells. In normal adults, haematopoiesis occurs primarily in the bone marrow and lymphatic tissues.
directly represses transcription of tumour suppressor genes such as ARF and NF1 through the AML1 DNA binding domain 45, 46 .
Acute promyelocytic leukaemia. All patients with APL have the t(15;17) translocation or one of its variants, which results in a fusion protein comprised of all but the first 30 amino acids of RARA 47 fused to a variable partner at its amino terminus 12, [48] [49] [50] [51] [52] . Wild-type RARA functions as a transcriptional activator, whereas the fusion protein functions as a transcriptional repressor through the recruitment of the HDAC, NCOR1 and NCOR2 (N-CoR) complex, DNMT1, DNMT3A, repressive histone methyltransferases and polycomb group proteins 53, 54 . In cells with PML-RARA translocations, treatment with pharmacological doses of ATRA 18, 19 relieves this repression by allowing the release of the N-CoR complex and the recruitment of a co-activator complex, which contains proteins with histone acetyltransferase (HAT) activity [55] [56] [57] . This results in the activation of RARA target genes as well as transcription factors crucial for normal haematopoiesis such as SPI1 (also known as PU.1) and C/EBPβ (CEBPB), with subsequent differentiation of leukaemia cells [55] [56] [57] . Patients with APL have a high complete response rate to ATRA used in conjunction with chemotherapy, and APL has served as a paradigm for the successful therapeutic targeting of epigenetic changes in acute leukaemia. Although the effects of ATRA on cellular differentiation are crucial to its success in APL, ATRA also results in the degradation of PML-RARA 58 , leading to growth arrest and a decline in leukaemia-initiating cells or leukaemia stem cells. Recently, the use of arsenic trioxide has also been found to result in the degradation of the PML-RARA fusion protein and apoptosis of APL cells. It also has significant clinical efficacy in the therapy of APL and can complement the use of ATRA in the treatment of patients with APL. In addition, treatment with arsenic trioxide potentially obviates the need for chemotherapy in some patients with this disease 55, 57, 59 . Gene expression and proteomic profiling experiments following treatment with both of these compounds reveal effects on multiple genes, including a pattern of upregulation of genes associated with myeloid differentiation and the downregulation of genes increasing cellular proliferation 55, 57, 60 . The synergistic effect observed with the combination of ATRA and arsenic trioxide in producing durable remissions in patients with APL has also been linked to the eradication of leukaemia stem cells 58 .
Leukaemias that disrupt HATs. Besides the recruitment of HDACs, DNMTs and co-repressor complexes, the scope of epigenetic deregulation by chromosomal translocations in acute leukaemias also includes a disruption of the actual enzymes that are involved in chromatin modification 61 . For example, HATs such as CREB binding [177] [178] [179] [180] [181] [182] . Recurrent genetic abnormalities have prognostic and therapeutic implications and also provide insights into the mechanisms of leukaemogenesis 178, 179, 182, 183 . Nature Reviews | Cancer protein (CBP; also known as CREBBP) and the closely related p300, as well as the monocytic leukaemia zinc finger (MOZ) and the related monocytic leukaemia zinc finger protein-related factor (MORF; also known as MysT4) are rearranged in chromosomal translocations in leukaemia. MOZ and MORF belong to the MysT family of HATs. The t(8;16) and t(10;16) translocations result in the fusion of two proteins with HAT activity: MOZ-CBP and MORF-CBP, respectively 62, 63 . The MOZ-CBP fusion inhibits AML1-mediated transcription, resulting in a differentiation block, and the HAT domain of CBP was found to be indispensable in this regard 64 . In addition, the HAT domain of MOZ also has a crucial role in haematopoiesis, with abrogation of the HAT activity in embryonic stem cell lines and mouse cell lines leading to a significant reduction in the proliferation potential of haematopoietic precursors 65 . Therefore, it is plausible that deregulation of CBP and MOZ-mediated acetylation by chromosomal rearrangements could lead to a disruption in the balance between proliferation and differentiation during haematopoiesis, and so contribute to the leukaemogenic phenotype.
An inversion on chromosome 8 (inv(8)) fuses the HAT domain of MOZ to the transcription factor TIF2 (also known as NCOA2) 66 . The MOZ HAT domain consists of a nucleosomal binding motif and an acetyltransferase catalytic domain (acetyl-CoA binding domain). Mouse models of the inv(8) fusion suggest that the nucleosomal binding domain of MOZ and the CBP interaction domain of TIF2 are essential for leukaemogenesis, whereas the N-terminal PHD domain and acetyl-CoA binding domain of MOZ are dispensable 67 . This implies that the MOZ-TIF2 fusion results in the deregulation of transcription through the aberrant recruitment of CBP to nucleosomal regions targeted by MOZ -the HAT activity of CBP might at least partly contribute to leukaemogenesis.
Translocation of mixed lineage leukaemia. The t(11;16) translocation, which fuses mixed lineage leukaemia (MLL) and CBP, is another example of a chromosomal translocation involving a protein with HAT activity 68 . MLL is located on chromosome band 11q23, has homology to the D. melanogaster trithorax gene (especially in the sET domain) and is involved in both myeloid and lymphoid leukaemias, as well as biphenotypic or mixed lineage leukaemias 69, 70 . MLL is involved in chromosomal translocations with more than 60 different partner genes in acute leukaemias, and the mechanism of leukaemogenesis by MLL fusion proteins remains perplexing given the disparate nature of the multiple known partner genes that have nuclear or cytoplasmic functions 71, 72 . However, because CBP had long been recognized to be a HAT, the MLL-CBP fusion protein provided an initial insight into potential mechanisms of leukaemogenesis induced by MLL fusions, and suggested that transcriptional deregulation through mechanisms linked to histone modifications and altered chromatin structure was important in disease pathogenesis 68 . subsequently, MLL was demonstrated to possess histone (H3K4) methyltransferase activity (and so transcriptional activation properties) through its carboxyterminal sET domain 73, 74 . MLL and the tumour suppressor protein menin (encoded by multiple endocrine neoplasia type 1 (MEN1)), which binds MLL at its N terminus, have been shown to associate with the homeobox A9 (HOXA9) promoter 75, 76 ; recently, the chromatin-associated protein PsIP1 (also known as LEDGF) has been shown to be a crucial cofactor for this interaction 77 . MLL H3K4 methyltransferase activity is associated with the activation of MLL target genes including Hoxa9 (REF. 74 ), which is important in the survival of MLL-rearranged leukaemias 78 . The absence of menin and/or PsIP1 results in a failure of MLL and MLL fusions to regulate Hoxa9 transcription, illustrating the importance of MLL-menin interaction in MLL fusion protein-induced leukaemogenesis 71, 77 . Despite the association of the sET domain with H3K4 methyltransferase activity and Hoxa9 activation, it is consistently lost in the MLL fusions, except for the partial tandem duplication of MLL (MLL-PTD), in which the sET domain and thereby the histone H3 lysine 4 (H3K4) methyltransferase activity is maintained 79 . Oncogeneic fusion proteins such as AML1-ETO, CBFB-MYH11 and PML-RARA recruit transcriptional co-repressor complexes (including nuclear receptor co-repressor 1 (NCOR1) and NCOR2) that result in the loss of histone acetylation and the acquisition of repressive histone modification marks, such as histone H3 lysine 9 (H3K9) methylation and H3K27 trimethylation, as well as DNA methylation, and thereby a closed chromatin structure. This leads to the transcriptional silencing of various target genes, including genes that are crucial for haematopoietic differentiation. Epigenetic or transcriptional therapy (targeting the fusion proteins, components of the co-repressor complexes and downstream effectors such as microRNAs) has the potential to reverse these changes, leading to histone acetylation, acquisition of active marks such as H3K4 methylation, an open chromatin structure with subsequent transcriptional activation and differentiation of the leukaemic clone. Ac, histone acetylation; AML1, acute myeloid leukaemia 1; CBFB, core binding factor-β; CpG, cytosine residues that precede guanosine; DNMT, DNA methyltransferase; HDAC, histone deacetylase; HMT, histone methyltransferase; PML, promyelocytic leukaemia; RARA, retinoic acid receptor-α; RNApolII, RNA polymerase II; TF, transcription factor.
French-American-British (FAB) classification of AML
The classification system divides AML into eight subtypes, M0 to M7, on the basis of the type of cells from which the leukaemia developed and the maturity of the cells.
However, MLL fusion-mediated leukaemogenesis is not as simple a process as perturbed MLL-dependent H3K4 methylation 74 . Indeed, for several of the MLL fusion proteins, the loss of the sET domain and H3K4 methyltransferase activity may potentially be compensated for by the acquisition of an alternative unique histone methyltransferase activity conferred by the partner proteins 71, 80 . For example, recent studies have shown that MLL fusion partners such as AF10, AF9, AF4 and ENL associate with the H3K79 histone methyltransferase DOT1L [81] [82] [83] . H3K79 methylation is also associated with transcriptional activation, and the acquisition of H3K79 methyltransferase activity has been demonstrated to be important for transformation by a subset of MLL fusion proteins 81, 84 . In a recently developed mouse model of MLL-AF4 leukaemia, genome-wide assessment of H3K79 methylation was carried out using a chromatin immunoprecipitation (ChIP)-chip technique, and approximately 1,000 promoters were found to be associated with increased H3K79 methylation compared with normal B cells 85 . Interestingly, short interfering RNA (siRNA)-mediated suppression of DOT1L decreased the expression of genes crucial for MLL fusion-mediated leukaemogenesis 85 , suggesting that the modification of H3K79 methylation may be a potential therapeutic strategy in leukaemias involving MLL fusions.
miRNAs in leukaemogenesis
Besides the two classic epigenetic modifications (that is, DNA methylation and histone modifications), a third epigenetic mechanism has recently gained attention, namely miRNA regulation. miRNAs are crucial regulators of many physiological processes such as development, cell apoptosis, differentiation and proliferation. Emerging evidence shows that altered miRNA expression is associated with various types of cancers [24] [25] [26] . In addition, miRNAs function in complex regulatory networks to regulate haematopoietic differentiation (supplementary information s1,s2 (box, table)) and contribute to leukaemogenesis [28] [29] [30] [31] The mir-17-92 polycistron located at 13q31, which contains seven individual miRNAs (miR-17-5p, miR-17-3p, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1), functions as an oncogene in various cancers including lymphoma, and lung, colon, pancreas and prostate tumours, medulloblastoma and multiple myeloma [86] [87] [88] . Recently, Li et al. 89, 90 showed that miRNAs in the mir-17-92 cluster are particularly overexpressed in acute leukaemia cells with MLL rearrangements, which is at least partly owing to the genomic DNA amplification of the locus 91 . Retroviral transduction of the mir-17-92 cluster significantly increased proliferation as well as the colony-forming and replating capacity of mouse normal bone marrow progenitor cells alone and particularly, in cooperation with the MLL-ELL fusion 91 . These data suggest that the mir-17-92 cluster may have an important role in the development of MLL-associated leukaemia. In normal haematopoiesis, mir-17-92 has an essential role in monocytopoiesis 92 and megakaryocytopoiesis 93 , and in B cell development [94] [95] [96] .
mir-17-92 is downregulated during monocytopoiesis and megakaryocytopoiesis and its forced expression represses monocytopoiesis (through targeting AML1)
92 and megakaryocytopoiesis 93 . mir-17-92 inhibits B cell development at the pro-B to pre-B transition probably through targeting PTEN and BIM [94] [95] [96] . Therefore, aberrant overexpresion of mir-17-92 in leukaemia inhibits normal haematopoiesis and thereby contributes to leukaemogenesis. In addition to the targets described above, E2F family transcription factors have also been suggested as both functional targets and regulators of mir-17-92 . Moreover, Li et al. 90 reported that 19 predicted targets of mir-17-92, including RASSF2 and RB1, were significantly downregulated in MLL-rearranged leukaemia and exhibit a significant inverse correlation with expression of the miRNAs. The direct regulation of RASSF2 and APP has been confirmed by using a luciferase reporter assay 90 . Therefore, a group of target genes of mir-17-92 has been identified and it is essential to determine which ones are crucial in leukaemogenesis.
miR-155 has an important role in megakaryopoiesis, erythropoiesis 93,100,101 and lymphopoiesis 102 . Transgenic mice with forced expression of miR-155 initially exhibit a preleukaemic pre-B cell proliferation evident in spleen and bone marrow, followed by a frank B cell malignancy, indicating that miR-155 can induce polyclonal expansion, favouring the occurrence of secondary genetic changes for full transformation 103 . In AML, miR-155 is specifically overexpressed in leukaemia with internal tandem duplication of the receptor tyrosine kinase FLT3 (FLT3-ITD) 104, 105 , but the upregulation of miR-155 is independent from FLT3 signalling 106 . miR-155 was reported to be overexpressed in a subset of AML (particularly M4 and M5 according to the French-American-British (FAB) classification of AML), and sustained expression of miR-155 in haematopoietic stem cells (HsCs) caused a myeloproliferative disorder 107 .
Box 1 | dna methylation and associated enzymes
DNA methylation is mediated by DNA methyltransferases (DNMTs), which catalyse the conversion of cytosine residues that precede guanosine (CpG) to 5-methylcytosine, by the covalent addition of a methyl group at the 5-carbon position of the cytosine 175 . These CpG residues are under-represented in the genome as a whole and occur at only 5-10% of the predicted frequency. This under-representation is probably linked to the propensity of methylated cytosine to undergo spontaneous deamination to thymidine, leading to the progressive depletion of CpG dinucleotides over time. CpG residues cluster particularly in the promoter regions of genes, in so-called CpG islands, and are generally unmethylated in normal cells. They are associated with hyperacetylated histones and an open chromatin configuration, which facilitates accessibility to transcription factors and transcriptional activation. CpG island methylation in the promoter regions of genes is associated with transcriptional repression, gene silencing and a condensed chromatin state and is seen physiologically, for example, in the context of genes silenced on the inactive X chromosome and imprinted genes.
The known enzymatically active DNMTs include DNMT3A and DNMT3B, which are de novo methylases and bind to both unmethylated and hemimethylated CpG sites. DNMT1 is responsible for maintaining DNA methylation patterns and binds preferentially to hemimethylated DNA.
Short-term repopulating HSCs
Haematopoietic stem cells (HsCs) are composed of short-term repopulating (sTR) and long-term repopulating (LTR) stem cells. sTR HsCs can sustain the haematopoietic system for only a short term, whereas LTR HsCs can reconstitute haematopoiesis for life.
Antagomir oligos
A class of chemically engineered antisense oligonucleotides that are complementary to either the mature miRNAs or their precursors and are used to specifically inhibit the activity of endogenous miRNAs, probably through irreversibly binding them. Antagomirs are used experimentally to constitutively inhibit specific miRNAs.
Nucleosomes
The basic units of chromatin that consist of approximately 146 base pairs of DNA wound around an octameric core of histone proteins: an H3-H4 tetramer and two H2A-H2B dimers.
miR-196a and miR-196b are significantly upregulated in AMLs with NPM1 mutations 104 and in MLL-associated paediatric ALL 108 , as well as in MLL-associated AML 89 . Popovic et al. 109 showed that during mouse embryonic stem cell differentiation, Mll normally regulates the expression of miR-196b in a pattern similar to that of the surrounding Hox genes, Hoxa9 and Hoxa10. In the haematopoietic lineage, the expression level of miR-196b reached a peak in short-term repopulating HsCs and then decreased as cells became more differentiated. Leukaemogenic MLL fusion proteins caused overexpression of miR-196b, and treatment of MLL-AF9-transformed bone marrow cells with miR-196-specific antagomir oligos abrogated their replating potential in methylcellulose. Forced expression of miR-196b in bone marrow progenitor cells led to increased proliferative capacity and survival, as well as a partial block in differentiation 109 . Consistently, miR-196 (and miR-21) is significantly downregulated by the transcriptional repressor GFI1 during the transition from common myeloid progenitors to granulocyte-macrophage progenitors, and forced expression of miR-196b (particularly when co-expressed with miR-21) significantly blocks granulopoiesis 110 . Therefore, miR-196 probably contributes to leukaemogenesis through increasing proliferation while blocking differentiation of haematopoietic progenitor cells. miRNAs as tumour suppressor genes in acute leukaemia. miRNAs have also been shown to function as tumour suppressors in acute leukaemia (TABLE 2) , although data in this area are more limited than for those miRNAs that function as oncogenes. The let-7 family is a wellknown tumour suppressor gene family, and functions as a negative regulator of a set of oncogenes including NRAS, KRAS and HMGA2 (REFs 111, 112) . In acute leukaemia, let-7b and let-7c were downregulated in CBF leukaemia cases 104 . On treatment of APL primary leukaemia samples and cell lines with ATRA, let-7a-3, let-7c and let-7d were upregulated, whereas their target Ras genes were downregulated 113 . The tumour suppressor property of miR-15a and miR-16-1 was first highlighted by the findings that they were deleted or downregulated in 68% of chronic lymphocytic leukaemias and targeted BCL2, an anti-apoptotic gene 114, 115 . In AML, miR-15a, miR-15b and miR-16-1 are upregulated while their target BCL2 is downregulated in APL cells after treatment with ATRA 113 . In addition, a MyB-miR-15a autoregulatory feedback loop was reported in which miR-15a targeted MyB and blocked the cells in the G1 phase of the cell cycle, while MyB bound the promoter region of miR-15a and was required for miR-15a expression; moreover, MyB and miR-15a expression was inversely correlated in cells undergoing erythroid differentiation 116 .
miRNA expression profiling in acute leukaemia. Li et al. 89 observed distinct miRNA expression patterns for t(15;17) translocations, MLL translocations and t(8;21) and inv(16) CBF fusions using large-scale, genomewide miRNA profiling in AMLs. Expression signatures of a minimum of two (that is, miR-126 and miR-126*), three (miR-224, miR-376c or miR-368 and miR-382), and seven (miR-17-5p and miR-20a, plus the previous five) miRNAs could accurately discriminate between CBF, t(15;17) and MLL-rearranged AMLs, respectively 89 . similarly, jongen-Lavrencic et al. 104 showed that miRNA signatures correlated with cytogenetic and molecular subtypes of AML (that is, AMLs with t(8;21), t(15;17), inv(16), NPM1 and CEBPA mutations). For example, all six AML cases with t(15;17) aggregated in a cluster; a significant upregulation of miR-10a, miR-10b, miR-196a and miR-196b was identified in AMLs with NPM1 mutations, and a significant upregulation of miR-155 was found in AMLs carrying FLT3-ITD. Notably, they also observed a significant upregulation of miR-126 in CBF leukaemia and a significant upregulation of miR-224 and miR-382 in t(15;17) AML 104 . The specific miRNA signature of t(15;17) (APL) cases and the upregulation of miR-10a and miR-10b in AMLs with NPM1 mutations and of miR-155 in AMLs with FLT3-ITD were also reported by others 105, 106, 117 . Marcucci et al. reported that miR-181a, miR-181a*, miR-181b, miR-181c, miR-181d, miR-128, miR-192, miR-219-1-3p, miR-224, miR-335 and miR-340 were upregulated whereas miR-34a and miR194 were downregulated in cytogenetically normal AMLs with CEBPA mutations 118 . In addition, the expression signature of some miRNAs was associated with the outcome and survival of patients with leukaemia. Garzon et al. 105 showed that patients with high expression of miR-191 and miR-199a had significantly worse overall and eventfree survival than patients with AML who had low expression. In cytogenetically normal AMLs, Marcucci et al. 119 found that the expression signature of
Box 2 | Histone modifications and associated enzymes
Structural studies have revealed that the amino-terminal tails of histones protrude outwards from the nucleosome and are subject to various post-translational modifications, including acetylation, methylation, ubiquitylation, phosphorylation, sumoylation and ADP-ribosylation 176 . Histone acetylation is associated with transcriptionally active chromatin (euchromatin) and is catalysed by histone acetyltransferases (HATs). Several transcriptional co-activators, including CREB binding protein (CBP) and p300, PCAF and NCOA1, have been shown to possess HAT activity. Conversely, transcriptional co-repressor complexes such as nuclear co-repressor 1 (NCOR1), NCOR2 (also known as SMRT) and SIN3A have been shown to contain subunits with histone deacetylase (HDAC) activity.
Histone methylation is catalysed by histone methyltransferases and can occur on lysine and/or arginine residues. In contrast to histone acetylation, which results in a transcriptionally active state, histone methylation can result in the activation or repression of transcription depending on the residue that is affected. For example, histone H3 lysine 4 (H3K4) methylation is recognized as an active mark associated with actively transcribed genes, and H3K20 trimethylation or H3K9 methylation are inactive marks associated with transcriptional repression and heterochromatic states. Histone methyltransferases also tend to be more specific with regard to their histone substrates, in contrast to HATs for example, and contain a conserved SET domain. Some of the histone methyltransferases identified in mammalians so far include SETD7, SMYD3 and mixed lineage leukaemia (MLL), which catalyse H3K4 methylation; SUV39H1, euchromatic histone-lysine N-methyltransferase 2 (EHMT2), EHMT1 and SETDB1, which catalyse H3K9 methylation; EZH2, which catalyses H3K27 methylation; and DOT1L, which catalyses H3K79 methylation.
Histone demethylases have recently been identified and include amine oxidases such as LSD1, which can demethylate H3K4 or H3K9 depending on the associated protein, and JmjC family members, which demethylate monomethylated, dimethylated and trimethylated lysine. Nature Reviews | Cancer miR-181a (using two probes) and miR-181b (using three probes) was associated with good outcome whereas that of miR-124, miR-128, miR-194, miR-219-5p, miR-220a and miR-320 (using two probes) was associated with poor outcome.
In a study of 17 ALL and 52 AML cases, Mi et al. 120 identified 27 miRNAs that were differentially expressed between ALL and AML. Among them, miR-128a and miR-128b were significantly overexpressed, whereas let-7b and miR-223 were significantly downregulated in ALL compared with AML. using the expression signatures of a minimum of two of these four miRNAs could distinguish ALL and AML with greater than 95% accuracy, indicating that expression signatures of as few as two miRNAs could accurately discriminate ALL from AML 120 . Notably, significant overexpression of miR-128 in ALL has also been reported elsewhere 108, 121 . Therefore, miRNA signatures correlate with cytogenetic and molecular subtypes of acute leukaemia, as well as the outcome of patients with leukaemia. Further large-scale miRNA expression profiling assays conducted by different groups are crucial to identify the miRNAs that can be reliable biomarkers for diagnosis and prognosis and/or therapeutic targets of leukaemia. , mir-17-92 (REFs 89, 90) and miR-196b 89, 108, 109 in mixed lineage leukaemia (MLL)-associated leukaemia (those with t(11q23)), and miR-224, miR-382 and the miR-376 family in acute promyelocytic leukaemia (APL) (t(15;17)) 89, 104, 117 . b | miRNAs upregulated or downregulated in acute myeloid leukaemia (AML) with gene or chromosomal abnormalities other than chromosomal translocation or inversion. These leukaemias can fall under any of the categories of AMLs in a, although with different distribution among them. In these leukaemias, possible biomarkers for classification and diagnosis include miR-196a and miR-196b 104 , and miR-10a and miR-10b 104, 106 in AML with nucleophosmin (NPM1) mutations, and miR-155 in AML with FMS-related tyrosine kinase 3 (FLT3)-internal tandem duplications (ITD) 104, 105 . ALL, acute lymphoblastic leukaemia; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; FAB, French-American-British classification; GMP, granulocyte-macrophage progenitor; HSC, haematopoietic stem cell; M2, acute myeloid leukaemia with maturation; M3, acute promyelocytic leukaemia; M4, acute myelomonocytic leukaemia; M4eo, M4 with eosinophilia; M5, acute monoblastic leukaemia; M6, acute erythroleukaemia; M7, acute megakaryoblastic leukaemia; MEP, megakaryocyte-erythrocyte progenitor; MPP, multipotent progenitor cell.
Leukaemic blasts
Abnormal immature white blood cells that are malignant (neoplastic). Typically found in the bone marrow and peripheral blood of patients with acute leukaemia. miRNAs as targets and effectors of the epigenetic machinery. It is now becoming clear that not only do miRNAs themselves function in an epigenetic manner by post-transcriptional regulation of expression of target genes, but they can also be targets of the epigenetic machinery, as well as effectors of DNA methylation and histone modifications. These functions may all have crucial roles in leukaemogenesis.
As examples of miRNAs as targets of the epigenetic machinery, their aberrant expression in acute leukaemia is directly associated with DNA methylation. For example, the increased expression of miR-126 and miR-126* in CBF AMLs and of miR-128 in ALL was associated with promoter demethylation 89, 120 . In addition, the fusion oncoproteins that arise from chromosomal translocations have been associated with epigenetic silencing of miRNAs. For example, expression of miR-223 is downregulated by the AML1-ETO fusion resulting from t(8;21) in AML 122 owing to a heterochromatic silencing of the miR-223 genomic region directly triggered by AML1-ETO. Increasing miR-223 expression through demethylation restores differentiation of leukaemic blasts 122 . similarly, transcriptional repression of miR-210, miR-23 and miR-24 by PML-RARA was reported in APL with the t(15;17) translocation 123 . Histone modifications may also have a role in the regulation of miRNA expression in acute leukaemia. Roman-Gomez et al. 124 observed high levels of dimethylation of H3 lysine 9 (H3K9me2) and/or low levels of trimethylation of H3 lysine 4 (H3K4me3) (these are patterns of histone modifications underlying a closed chromatin structure that is associated with repressive gene expression) in CpG islands around 13 miRNAs. Their analysis of 353 patients with primary ALL showed that 65% of the ALL samples had at least 1 methylated miRNA. Notably, patients with miRNA methylation had a significantly poorer disease-free survival (DFs; 24%) than patients with unmethylated miRNAs (78%) and overall survival (Os; 28% compared with 71%). Multivariate analysis demonstrated that the patient's methylation profile was an independent prognostic factor for predicting DFs and Os. Their results suggest that aberrant miRNA methylation is a common phenomenon in ALL and that miRNA methylation profiles might be important in predicting the clinical outcome of patients with ALL 124 . Conversely, miRNAs might also function as effectors of the epigenetic machinery. Two recent studies 125, 126 show that miR-290, a mouse embryonic stem cellspecific miRNA, controls DNA methylation and telomere recombination through retinoblastoma-like 2 (Rbl2)-dependent regulation of DNMTs. In leukaemia, forced expression of miR-29b in AML cells induced global DNA hypomethylation and re-expression of tumour suppressor genes including INK4B and oestrogen receptor 1 (ESR1) by targeting DNMT3A and DNMT3B directly and DNMT1 indirectly 127 .
Epigenetic therapy in acute leukaemia unlike gene deletions that lead to an irreversible loss of function, transcriptional repression by epigenetic mechanisms such as histone deacetylation and promoter DNA ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; APL, acute promyelocytic leukaemia; APP, amyloid-β (A4) precursor protein; ATRA, all-trans retinoic acid; CDKN1A, cyclin-dependent kinase inhibitor 1A; CEBPB, C/EBPβ; CMP, common myeloid progenitor; FLT3, FMS-related tyrosine kinase 3; FOXP3, forkhead box P3; GMP, granulocyte-macrophage progenitor; Hox, homeobox; HSCs, haematopoietic stem cells; INPP5D, inositol polyphosphate-5-phosphatase; ITD, internal tandem duplication; MAP3K7IP2, MAPK kinase kinase 7 interacting protein 2; miRNA, microRNA; MLL, mixed lineage leukaemia; ND, not determined; NPM1, nucleophosmin; PTEN, phosphatase and tensin homologue; STR-HSCs, short-term repopulating HSCs.
Myelodysplastic syndrome
A group of clonal haematopoietic stem cell disorders characterized by cytopenias (low blood counts) and ineffective haematopoiesis, dysplasia in one or more myeloid cell lines, and an increased risk of transformation to AML. methylation can be reversed by pharmacological inhibitors of such processes. One of the best known and most successful examples of targeted therapy that can induce epigenetic changes is the use of ATRA in the therapy of APL, which has been described above. Because epigenetic mechanisms are crucial to the pathogenesis of acute leukaemias, there has been considerable interest in the investigation of agents that target the epigenome in these diseases.
Histone deacetylase inhibitors (HDACIs).
HDACIs have been associated with effects on various genes, including those involved with cell cycle regulation, apoptosis and angiogenesis. HDACIs exert anti-tumour effects in vitro and in vivo, and are now in clinical trials for acute leukaemias, as well as related neoplastic disorders of the bone marrow such as myelodysplastic syndromes (MDs) and myeloproliferative neoplasms. In preclinical studies, HDACIs have been shown to induce differentiation of APL cell lines, including those resistant to standard differentiating therapy with ATRA [128] [129] [130] . They abolish tumours with t(15;17) translocations in nude mice, and induce remissions in transgenic mouse models of ATRA-resistant APL 130, 131 . HDACIs also induce differentiation and apoptosis of t(8;21) leukaemia cell lines and primary leukaemia blasts 39, [132] [133] [134] . In the clinical setting, therapy with the HDACI sodium phenylbutyrate has been shown to restore ATRA responsiveness in a patient with APL who had experienced multiple relapses and was clinically resistant to therapy with ATRA alone 135 . Treatment with phenylbutyrate induced a complete clinical and cytogenetic remission and a time-dependent histone acetylation in peripheral blood and bone marrow mononuclear cells 135 . However, butyrates are short-chain fatty acids and generally not very potent in inhibiting HDACs 136 . More potent HDACIs, including hydroxamic acids, cyclic tetrapeptides and benzamides, have been developed and are under clinical investigation 137 . Currently, advanced primary cutaneous T cell lymphoma is the only tumour in which significant efficacy of an HDACI, sAHA (vorinostat), has been demonstrated in the clinic. This resulted in its approval by the us Food and Drug Administration (FDA) for the treatment of this disease 138 . Most clinical trials using HDACIs as single agents in patients with advanced AML or MDs have demonstrated limited clinical activity [139] [140] [141] [142] [143] [144] [145] [146] [147] (TABLE 3) . Recently, published preclinical studies have also focused on distinct cytogenetic subsets of AML such as CBF AML, a cytogenetic subset that is thought to be particularly amenable to therapy with this class of drugs, on the basis of transcriptional repression through HDAC recruitment by the oncogenic fusion proteins 132, 133 . In a recent clinical trial, transient anti-leukaemia activity was demonstrated in patients with advanced CBF leukaemia treated with the HDACI romidepsin, and this was associated with the upregulation of AML1-ETO target genes 146 . Given the limited single agent activity of HDACIs in acute leukaemias, ongoing trials are investigating the combination of HDACIs with other agents, including DNMT inhibitors (TABLE 3) .
DNMT inhibitors. Although DNMT inhibitors have existed for several decades, they were originally used at high doses, which resulted in substantial cytotoxicity and an unacceptable toxicity profile 148 . At lower doses, however, the DNA demethylating and differentiating effects of these drugs predominate, and they are active in a broad range of myeloid neoplasms, including MDs, myeloproliferative neoplasms and AML 149 . The DNMT inhibitors in clinical and/or preclinical development fall into two broad categories: nucleoside analogues and non-nucleoside demethylating agents 137, 149 . The prototypic nucleoside analogue DNMT inhibitors 5-azacytidine (also known as 5-Aza or azacitidine) and 5-aza-2′deoxycytidine (also known as decitabine), are both incorporated into DNA (5-Aza is also incorporated into RNA) and form a covalent complex with the DNMT enzyme resulting in the trapping and degradation of the enzyme and progressive loss of DNMT activity in cells. Both compounds have recently been approved by the us FDA for the treatment of MDs [150] [151] [152] . Objective response rates (complete and partial responses) in these trials ranged from 20% to 30%, but an additional 20-30% of patients derive clinical benefit in terms of improvement in blood counts or the number of blood transfusions required (haematological improvement), despite evidence of the persistence of significant disease in the bone marrow 150, 152, 153 . several of the trials conducted in MDs have included patients who have a myeloblast count of 20-30% in the bone marrow (and are therefore considered to have AML), and in these patients the overall response rates, including haematological improvement, have ranged from 35% to 48% 154 . There are now several early-phase trials using DNMT inhibitors, as either single agents or in combination with other agents, which confirm the clinical activity of this group of drugs in AML [155] [156] [157] [158] [159] [160] [161] [162] , including elderly patients with AML who are unable to tolerate standard cytotoxic chemotherapy [155] [156] [157] . It is important to note that DNMT inhibitors can require several cycles of administration for activity to be demonstrated. This might be because repetitive administration is necessary for progressive demethylation and epigenetic modulation of crucial genes, such as cell cycle regulatory and pro-apoptotic genes. In addition, the effects of these drugs on methylation are not permanent, and therefore chronic exposure is required to maintain the effects. The clinical activity of these agents is thought to be mediated through the reversal of epigenetic silencing and there are some published clinical trials that support this hypothesis 158, 163 . However, in general this has been challenging to prove conclusively in the clinical setting 156, 160, 164 (TABLE 3), and it is likely that alternative mechanisms of action, such as the induction of DNA damage 159, [165] [166] [167] , might contribute to the pleiotropic effects of these drugs.
Efforts are ongoing to develop DNMT inhibitors that have greater selectivity for cancer cells and that are suitable for chronic oral administration in the clinical setting. In addition, given the inter-relationship between DNA methylation and histone modifications in the regulation of gene expression 168 , it is not surprising that HDACIs and DNMT inhibitors are being combined in clinical trials in AML and MDs (TABLE 3) in an effort to optimize the anti-tumour activities of these agents and recapitulate the synergistic interaction that has been demonstrated in the preclinical setting. several of these published trials have been conducted using low potency HDACIs [155] [156] [157] [158] and have shown the feasibility of this approach, but have not demonstrated a clear contribution of the HDACIs to the clinical or biological activity of the combination 155 . The results from ongoing randomized trials with newer, more potent HDACIs will be necessary to validate the synergy between these two classes of epigenetic modulators in patients with AML and MDs. miRNAs as potential therapeutic targets and tools. Because they can function as oncogenes or tumour suppressor genes in leukaemogenesis, miRNAs also have the potential to be therapeutic targets or tools. miRNA-based cancer gene therapy offers the chance of targeting multiple gene networks that are controlled by a single, aberrantly expressed miRNA 169 . Reconstitution of a tumoursuppressive miRNA, or sequence-specific knockdown of oncogenic miRNAs by antagomir oliogos, has produced favourable anti-tumour outcomes in experimental models 169 . In addition, the efficacy of some existing clinical therapeutic approaches may be mediated through the modulation of miRNA expression. For example, tumour suppressor miRNA upregulation has been demonstrated with the use of ATRA in APL cell lines and primary leukaemia samples 113, 123 , and the DNMT inhibitor 5-azacytidine has been associated with the reversal of epigenetic silencing of an miRNA linked to the differentiation block in AML1-ETO AML blasts 122 . However, there are still many issues to be resolved before consideration of conducting miRNA-based clinical therapy, including dosage, efficacy, functionality, delivery, nonspecific toxicity and immune activation 24, 169 . In addition, because of the redundancy of some miRNA families or functional redundancy of a set of miRNAs that are not in a family, targeting a single member might not be sufficient in terms of gene therapy. In such cases, simultaneously targeting several miRNAs would be crucial. Furthermore, some miRNAs can have a different role (as oncogenes or tumour suppressors) depending on the cellular context. For example, the mir-17-92 cluster is a well-known oncogene in various types of cancers 86, 87, 89, 170, 171 , including leukaemia 89, 104, 108, 109 , but can function as a tumour suppressor gene in breast cancer 172, 173 . Therefore, before considering a potential clinical application, it is important to understand the expression pattern and potential role of the candidate miRNA(s) in other tissues to avoid causing undesirable side effects.
conclusions and perspectives
The complexity and biological heterogeneity of acute leukaemias poses considerable challenges to therapeutic advances. It is clear, however, that an in-depth understanding of the biology of acute leukaemias is essential to make meaningful progress. The oncogenic fusion proteins in acute leukaemia associate in macromolecular complexes, lack intrinsic enzymatic activity and are therefore not easily druggable. This is in contrast to the clinical development of ABL kinase inhibitors in CML, for example. Epigenetic and transcriptional therapeutic strategies that focus on the disruption of the association of oncoproteins with substrate DNA or interference with key molecules that oncoproteins may associate with to promote leukaemia (such as the disruption of the MLL-MEN1 interaction) hold promise for the future. In addition, besides the ongoing clinical studies of HDACIs and DNMT inhibitors, other components of the epigenetic regulatory machinery, such as histone methyltransferases, histone demethylases, HATs and sirtuins, are potential targets for future anticancer and anti-leukaemia therapy 174 . The importance of miRNAs in increasing our basic knowledge about the pathobiology of leukaemias as well as their therapeutic potential and some of the potential pitfalls that could be encountered in clinical translation have been mentioned above. Given the importance of cooperating gene mutations in signalling pathways in the generation of the acute leukaemia phenotype, it is likely that the most effective treatment strategies in the future will involve a combination of rationally designed transcriptional treatment approaches with those that inhibit relevant activated signal transduction molecules. 23-36 (2010) In table 2 on page 30 of the above article, the reference for miR-196a and miR-196b was mistakenly indicated as reference 103. Accordingly, this reference has been replaced with references 89, 104 and 108-110.
